<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Macquarie_Australia_Singapore skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Macquarie Australia/Singapore</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV id="TopBar"><UL id="TopLvlNav"><LI><A href="https://2016.igem.org/Team:Macquarie_Australia">Home</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Description">Project</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Description">Description</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Results">Results</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/interlab">Interlab study</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/protocols">Protocols/Testing</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Notebook">Notebook</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Safety">Safety</A></LI></UL><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Parts">Parts</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Summary">Summary Table</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Composite_Part">Best Composite Part</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Part_Collection">Part Collection</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Proof">Proof of Concept</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Model">Model</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Theoretical">Theoretical</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Experimental">Experimental</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Demonstrate">Demonstration</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Integrated_Practices">Human Practices</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/HP/Gold">Integration</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/HP/Silver">Outreach</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Students">Team</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Students">Students</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Advisers">Advisors</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Sponsors">Sponsors</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Achievements">Achievements</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Collaborations">Collaborations</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Singapore ">NTU Singapore</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/Paris">Paris Bettencourt</A></LI><LI><A href="https://2016.igem.org/Team:Macquarie_Australia/South Africa">Other</A></LI></DIV><HEADER><DIV class="ex1" align="justify"><H1><FONT face="Arial"><CENTER><SPAN style="font-weight:normal; font-size: 23pt" font="" style="line-height:1.5">Singapore iGEM Team</SPAN></CENTER></FONT></H1><FONT face="Corbel" font="" style="line-height:1.5" font="" size="3" color="#404040">
After reading that we were continuing on from last yearâ€™s project, the <A href="https://2016.igem.org/Team:NTU-Singapore/Collaborations"><B>NTU-Singapore team</B></A> approached us offering to help us knock in our very large plasmids (&gt;10kbp). After further discussion we decided against this option as it would be too hard to coordinate in the little time we had left (September to October)</FONT>.
<FONT face="Corbel" font="" style="line-height:1.5" font="" size="3" color="#404040">
Coincidentally, we started a CRISPR-Cas<FONT face="arial">9</FONT> approach this year as well. This led to the sharing of ideas and developed into other possible collaborative work. For our CRISPR-Cas<FONT face="arial">9</FONT> project, we managed to show in vitro that our gRNA-Cas<FONT face="arial">9</FONT> complex was able to target and cleave the PCR product of our target gene, <I>hem</I>H. This assay also provides a quick and easy test to their Cas<FONT face="arial">9</FONT>, which was their overall goal. Our collaboration involved testing their Cas<FONT face="arial">9</FONT> in bacterial cells which would help to characterise their Cas<FONT face="arial">9</FONT> functions when compared against the commercial Cas<FONT face="arial">9</FONT> we acquired for our own experiments.</FONT><FONT face="Corbel" font="" style="line-height:1.5" font="" size="3" color="#404040">
To facilitate this, NTU-Singapore did a purification tag switch (FLAG to 6xHis) so that we could purify their mutants of interest with high yields for characterisation using our in vitro assay design. In return, they attempted to help us generate a <I>hem</I>H knockout, and perform RT-PCR on our Magnesium chelatase plasmid containing 6 genes, for which we have functional assays to show that it works.</FONT><FONT face="Corbel" font="" style="line-height:1.5" font="" size="3" color="#404040"><B>In summary what we did for them: </B><OL><LI>Sent the NTU-Singapore team our Mg-chelatase operon plasmids and primers designed
for each gene for the RT-PCR </LI><LI>Purified and characterised their Cas<FONT face="arial">9</FONT> mutants of interest proving their mutant enzyme functions </LI></OL><B>What they did for us:</B><OL><LI>Sent us their Cas<FONT face="arial">9</FONT> mutant plasmids after cloning in a His-tag</LI><LI>Attempted to generate <I>hem</I>H Knockout</LI><LI>Performed RT-PCR of the genes in our Mg-chelatase operon</LI></OL></FONT><DIV class="align: center"><FIGCAPTION><FONT face="Corbel" font="" style="line-height:1.5" font="" size="3" color="#404040"><CENTER><B>Fig 1.</B> Digests of the Ferrochelatase PCR product target, by the two Cas<FONT face="arial">9</FONT> mutants, and the wild type Cas<FONT face="arial">9</FONT>.
 </CENTER></FONT></FIGCAPTION></DIV><FONT face="Corbel" font="" style="line-height:1.5" font="" size="3" color="#404040">
Shown above are the <I>in vitro</I> confirmations of the functional CRISPR/Cas<FONT face="arial">9</FONT>
 from NTU-Singapore. The three Cas<FONT face="arial">9</FONT>  proteins that were studied in this experiment:
 wild type (Wt), <A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2130002"><B>459 mutant (BBa_K2130002)</B></A>, <A href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K2130001"><B>462 mutant (BBa_K2130001)</B></A></FONT>. <FONT face="Corbel" font="" style="line-height:1.5" font="" size="3" color="#404040">All three were 
 seen to cut our Ferrochelatase PCR product target, amplified in earlier weeks. This digestion was confirmed against 
 the negative control without 
 Cas<FONT face="arial">9</FONT>, and the commercial Cas<FONT face="arial">9</FONT>, as the Ferrochelatase
 was seen to be accurately cleaved into a 850bp fragment and a 150bp fragment, the lower band of less than 100bp is the excess gRNA duplex. From our efforts, we
 have proven that their mutant Cas<FONT face="arial">9</FONT> is functional <I>in vitro</I>, providing first evidence for the NTU Singapore team that these 2 mutants are functional nucleases. 

</FONT></DIV></HEADER></DIV></DIV></DIV></DIV></DIV></BODY></HTML>